Olopatadine versus levocetirizine in chronic urticaria: An observer-blind, randomized, controlled trial of effectiveness and safety

Journal of Dermatological Treatment

Volumn 24, Issue 6, 2013, Pages 466-472

  Sil, Amrita ^a   Tripathi, Santanu Kumar ^b   Chaudhuri, Anita ^c   Das, Nilay Kanti ^d   Hazra, Avijit ^e   Bagchi, Chiranjib ^b   Islam, Chowdhury Nazrul ^e  

^a BURDWAN MEDICAL COLLEGE   (India)

^b CALCUTTA SCHOOL OF TROPICAL MEDICINE   (India)

^c BURDWAN MEDICAL COLLEGE AND HOSPITAL   (India)

^d MEDICAL COLLEGE AND HOSPITAL   (India)

^e INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Chronic urticaria; dermatologic life quality index; Olopatadine; Randomized controlled trial; Urticaria activity score; Urticaria total severity score

Indexed keywords

LEVOCETIRIZINE; OLOPATADINE;

ADULT; ARTICLE; CHRONIC URTICARIA; CONSTIPATION; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG SAFETY; EPIGASTRIC DISCOMFORT; FATIGUE; FEMALE; HEART PALPITATION; HUMAN; INCREASED APPETITE; LABORATORY TEST; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; TREATMENT DURATION; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-ALLERGIC AGENTS; CETIRIZINE; CHRONIC DISEASE; DIBENZOXEPINS; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; URTICARIA; YOUNG ADULT;

EID: 84887860167     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2012.750414     Document Type: Article

References (29)

1. Greaves MW, Sabroe RA. Allergy and the skin I: Urticaria. Br Med J. 1998;316:1147-1150
2. Sheldon JM, Mathews KP, Lovell RG. The vexing urticaria problem: Present concepts of etiology and management. J Allergy. 1954;25: 525-560
3. Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. The effectiveness of a history-based diagnostic approach in chronic urticaria and angioedema. Arch Dermatol. 1998;134:1575-1580
4. Lindelof B, Sigurgeirsson B, Wahlgren CF, Eklund G. Chronic urticaria and cancer: An epidemiological study of 1155 patients. Br J Dermatol. 1990;123:453-456
5. Warin RP. Food and factors in urticaria. J Hum Nutr. 1976;30:179-186
6. Sabroe RA, Greaves MW. The pathogenesis of chronic idiopathic urticaria. Arch Dermatol. 1997;133:1003-1008
7. Hellgren L, Hersle K. Acute and chronic urticaria. A statistical investigation on clinical and laboratory data in 1204 patients and matched healthy controls. Acta Allergol. 1964;19:406-420
8. Sehgal VN, Rege VL. An interrogative study of 158 urticaria patients. Ann Allergy. 1973;31:279-283
9. Kaplan AP, Horakova Z, Katz SI. Assessment of tissue fluid histamine levels in patientswith urticaria. J Allergy Clin Immunol. 1978;61:350-354
10. Phanuphak P, Schocket AL, Arroyave CM, Kohler PF. Skin histamine in chronic urticaria. J Allergy Clin Immunol. 1980;65:371-375
11. Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride: A new antiallergic drug. Jpn J Pharmacol. 2002;88:379-397
12. Giustizieri ML, Albanesi C, Fluhr J, Gisondi P, Norgauer J, Girolomoni G. H1 receptor mediates inflammatory responses in human keratinocytes. J Allergy Clin Immunol. 2004;114:1176-1182
13. Ciprandi G, Cirillo I, Vizzaccaro A, Tosca MA. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: A pilot study. Clin Exp Allergy. 2004;34: 958-964
14. Furukawa H, Takahashi M, Nakamura K, Kaneko F. Effect of an antiallergic drug (Olopatadine hydrochloride) on TARC/CCL17 and MDC/CCL22 production by PBMCs from patients with atopic dermatitis. J Dermatol Sci. 2004;36:165-172
15. Okubo Y, Shigoka Y, Yamazaki M, Tsuboi R. Double dose of cetirizine hydrochloride is effective for patients with urticaria resistant: A prospective, randomized, non-blinded, comparative clinical study and assessment of quality of life. J Dermatolog Treat. 2011;Epub ahead of print
16. Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, et al. The effectiveness of levocetirizine and desloratidine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125:676-682
17. Philpott H, Kette F, Hissaria P, Gillis D, Smith W. Chronic urticaria: The autoimmune paradigm. Intern Med J. 2008;38:852-857
18. Anuradha P, Maiti R, Jyothirmai J, Mujeebuddin O, Anuradha M. Loratidine versus levocetirizine in chronic idiopathic urticaria: A comparative study of efficacy and safety. Indian J Pharmacol. 2010;42:12-16
19. Godse KV. Olopatadine in chronic idiopathic urticaria. Indian J Dermatol. 2009;54:191-192
20. Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: A single-blind, placebocontrolled, crossover clinical study. J Aller Clin Immunol. 2002;110: 484-488
21. Bajaj AK, Upadhyay A, Damisetty R, Dhar S. Autologous serum therapy in chronic urticaria: Old wine in a new bottle. Indian J Dermatol Venereol Leprol. 2008;74:109-113
22. Bonifati C, Berardesca E. Clinical outcome measures of psoriasis. Reumatismo. 2007;59:64-67
23. Finlay AY. Quality of life indices. Indian J Dermatol Venereol Leprol. 2004;70:143-148
24. Kozel MM, Mekkes IR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angieoedema in 220 patients. J Am Acad Dermatol. 2011;45:387-391
25. Potter PC, Kapp A, Maurer M, Guillet G, Jian AM, Hauptmann P, et al. Comparison of the efficacy of levocetirizine 5 mg and desloratidine 5 mg in chronic idiopathic urticaria patients. Allergy. 2009;64:596-604
26. Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002;88:379-397
27. Takahashi H, Zhang Y, Morita E. Evaluation of the antihistamine effects of olopatadine, cetirizine and fexofenadine during a 24 h period: A double-blind, randomized, crossover, placebo-controlled comparison in skin responses induced by histamine iontophoresis. Arch Dermatol Res. 2008;300:291-295
28. Hashimoto T, Ishii N, Hamada T, Dainichi T, Karashima T, Nakama T, et al. Effects of olopatadine hydrochloride, a histamine H1 receptor antagonist, on histamine-induced skin responses. Dermatol Res Pract. 2010; Epub 2010 Sep 16
29. Dubuske LM. Levocetirizine: The latest treatment option for allergic rhinitis and chronic idiopathic urticaria. Allergy Asthma Proc. 2007;28:724-734